Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

CAMS Oxford Institute Group Leader and Career Development Fellow, Adán Pinto-Fernández, has been awarded a highly competitive 2-year project grant by Boehringer Ingelheim through their Open Innovation Portal initiative, opnMe.

CAMS Oxford Institute Group Leader and Career Development Fellow, Adán Pinto-Fernández, has been awarded a highly competitive 2-year project grant by Boehringer Ingelheim through their Open Innovation Portal initiative, opnMe. Out of 31 submissions from 12 countries, Adán's proposal was selected to address Boehringer Ingelheim’s challenge on the "stabilization of protein-protein interactions to target cancer cells."

The project, led by Adán Pinto-Fernández, will focus on enhancing a specific protein-protein interaction with significant therapeutic potential in the field of immuno-oncology. By collaborating closely with a dedicated team at Boehringer Ingelheim, Adán's group aims to contribute to the development of innovative cancer therapies that leverage the body's immune response.

"We are honoured to have our proposal chosen from such a competitive field and to work alongside the outstanding scientists from a prestigious institution like Boehringer Ingelheim. This grant will enable us to delve deeper into the mechanisms of protein-protein interactions and explore new avenues for cancer treatment." – Adán Pinto-Fernández.

This collaboration with Boehringer Ingelheim will bring together the expertise of both teams, fostering an environment of innovation and shared knowledge. This partnership is expected to yield insights that could pave the way for novel treatments in immuno-oncology. 

For more information on Adán Pinto-Fernández's research at COI, please visit the Pinto-Fernández Group Page